



AlphaScreens: the quest for quality

# 4 April 2022

# Conflicting quality signals

The holy grail for buy-and-hold investors is to find a business that is capable of generating a high return on capital and sustaining it while reinvesting profits. This screen looks for shares that display these quality characteristics and can potentially deliver significant compounded returns over time. The Alpha screens now use the Numis index family for their starting universe for UK large, mid and small-cap shares. We also now have a US screen of S&P 500 companies.

#### Comment by Alpha editor:

- Top of our UK large-cap screen is software and cybersecurity company **Avast (AVST)**, which saw its shares fall sharply in March on news the Competition and Markets Authority (CMA) wanted to refer the agreed merger with NortonLifeLock to a Phase 2 investigation. The parties involved in the merger expect it to complete in the second half of 2022, noting that other regulators in the USA, Germany and Spain have reviewed and cleared the merger.
- Other high ranking UK large-cap shares include miner **BHP Group (BHP)** and, representing another controversial sector, **British American Tobacco (BATS)**. In the case of BHP, the concern would be the cyclical nature of the industry and it fails our next year earnings per share growth test. Really, mining stocks wouldn't fit a textbook definition of 'quality' thanks to these cyclical risks. However, given the potential for stagflation (recession accompanied by inflation), miners that are exposed to rising commodity prices and have a track record of returning cash to shareholders via dividends and buybacks are a useful holding. In rare times of stagflation, tobacco stocks like BATS are also good for investors who don't have a moral issue with them. Low growth in much of the economy means dividends are a really important part of total returns, so the inelastic demand for tobacco products and the subsequent payouts from the manufacturers to shareholders are tempting.
- One company that made it into the list but **must be disregarded** for obvious reasons is Russian-linked steel manufacturer **Evraz (EVR)**. Although it passes seven out of nine tests, the reality of the international situation isn't shown by the numbers.
- Many very profitable quality companies are still expensive, both those listed on the UK and the US stock markets. Still, it is notable that the negative three-month share price momentum for names like **Diageo (DGE)** in the UK and **Apple (US:AAPL)** and **Microsoft** (**US:MSFT)** from our S&P 500 screen is in the single digits, despite the hawkish signals from





central banks (higher interest rates make profits made by these big earners not worth paying so much for). As aggressive rate hikes are better priced in, it will be worth looking to identify where the support level prices are for these businesses that have enduring quality characteristics.

• Looking at our small-cap screen, which covers smaller Aim and main market UK shares, the outputs are better interpreted with a cyclical mindset rather than looking at stocks that can be bought and forgotten about. Mining companies are prominent, which underlines this point. It's also interesting to see companies that have experienced relatively heavy sell-offs in their shares scoring highly on quality metrics. The many small-cap screen results here definitely fall into the "investigate further" bucket, rather than being screaming "buys".


Screen results on pages 7, 8 and 9, at the end of this report

## The dream company

The holy grail for buy-and-hold investors is to find a business that is capable of generating high returns on its capital and is able to reinvest all its profits for decades to come, while maintaining those returns. The compounding effect of such an investment is what every long-term investor's dreams should be made of. A company making a consistent 15 per cent post-tax return on its equity and reinvesting all its profits would experience a near-30-fold (28.6 to be precise) growth in its equity base over 25 years, and after 50 years it would be a mind-boggling 1,084 times bigger than when it started. For a patient investor convinced that they have found such a situation, valuation should not act as a major impediment to a purchase.








Source: Refinitiv, Investors' Chronicle

Unfortunately, this kind of dream company is extremely rare and stock screens are too crude to provide the depth of analysis needed to provide confidence that a business may be the real deal. In particular, it is inevitable that some of the shares highlighted by our Alpha Quality screen will be cyclical companies that are enjoying a good run rather than companies that are well placed to sustain high returns through many business cycles to come. What our screen does do, however, is attempt to find pointers for companies that may have the potential to go some way to filling the dream brief. What's more, buying shares in companies that look attractive based on quality metrics can often prove a profitable strategy, even if many of the shares picked fall short of the buy-and-hold ideal.







Source: Refinitiv, Investors' Chronicle

## Alpha Quality screening criteria

Our Alpha Quality screen uses two key measures of quality, which are operating margins and return on equity (RoE). The advantage of using RoE to measure the quality of a company is that it focuses on the returns that are ultimately of most significance to shareholders: after-tax earnings. However, RoE can be boosted by a company if it increases the amount of debt it carries. That means a high and rising RoE can sometimes simply reflect a reduction in the quality of the company's balance sheet and little improvement, or even a deterioration, in the quality of its operations. The screen attempts to counter this with its interest cover test, which should help it avoid companies with very aggressively 'geared' balance sheets. Focusing on operating margins also provides an assessment of quality at the operating level – i.e. before the impact of debt.

- An operating margin higher than the median average (mid-ranking) stock in each of the past three years (i.e. quality that shows some signs of persistence).
- A return on equity (RoE) higher than the median average (mid-ranking) stock in each of the past three years (i.e. again, quality that shows some signs of persistence).





- RoE higher than it was two years ago (i.e. quality is improving as well as persistent).
- Operating margin higher than it was two years ago (i.e. quality is improving as well as persistent).
- A dividend-and-debt adjusted price/earnings growth (PEG) ratio below the top fifth of stocks screened (ie stocks must not be too egregiously expensive for the growth on offer).
- A price/earnings (PE) ratio above the bottom 10 per cent of stocks screened and below the top 10 per cent (i.e. not a suspiciously cheap or dangerously expensive valuation).
- Interest cover of more than five (i.e. high RoE is not overly dependent on the use of debt).
- Forecast earnings growth for each of the next two financial years.
- Positive free cash flow.

Not many stocks pass such a stringent list of criteria. The ones that pass all the tests are listed at the top of the table, followed by those failing one test, then those failing two tests as detailed in the 'Tests passed' column. Ordinarily, all stocks must pass the test for three-year, higher-than-average RoE and margin to feature in the table, but these requirements have been relaxed due to the pandemic. While the primary ranking of the stocks is based on the number of tests they pass, inside each of these groupings stocks are ordered according to their attractiveness based on operating margin and three-month share price momentum.

## New indices, a tighter set of ideas

Going forward, we're switching to screening in an equities universe inspired by the Numis family of UK indices. The aim is to give investors a true overview of genuine large-cap, mid-cap and small-cap quality shares.

We will also be excluding investment trusts from results. The purpose of these screens is to highlight individual companies that are worth investigating further. Including closed-end funds in the universe skews the results and distracts from that objective. Investment trusts are given their own, far more detailed, analysis in the regular Alpha Investment Trust report.





#### Breakdown of the Numis indices we have been inspired by:

Numis Large-Cap index (excluding investment companies/trusts): This includes the top 80 per cent of companies by market capitalisation that are listed on the UK main market. The lower size cut-off for 2022 is £4.12bn market cap.

**Numis Mid-Cap** index (excluding investment companies/trusts): This includes the 15 per cent of UK main market listed companies below the top 80 per cent but above the bottom five per cent by market capitalisation. The upper size cut-off is £4.12bn and the lower cut-off is £880mn market cap.

**NSCI** (Numis Small Companies Index), version excluding investment trusts: This includes the bottom 10 per cent of the UK main market by market capitalisation (so there is overlap with the Numis Mid Cap index). The upper size cut-off is £1.64bn market cap.

**NSCI plus Aim**, version excluding investment trusts: This adds all Aim companies below the £1.64bn market cap cut-off to the NSCI.

#### Performance tracking

Clearly, we won't be able to claim the back-tested performance of the Investors' Chronicle Quality screens, which are based on all the companies in the FTSE All-Share. The deconstructed performance of shares selected from that universe will be attributable to a different set of size and beta factors to the ones we will be exposed to.

Back-testing in general is a very dangerous tool. One needs to guard against survivorship bias in an index and look-ahead bias (factoring in data that although it relates to a period, wouldn't have been known at the time). Therefore, this is year zero for the performance tracking of the screens. Finally, it is worth reiterating the purpose is to flag ideas. What the screens do not do is generate off-the-shelf portfolios.

#### American adventure

One no-brainer addition to the Alpha screens is to add American companies to the mix. We've run our methodology against the S&P 500 and there are so many companies ranking well on the criteria we are only showing those that get full marks.





Alpha Fi oddction Editor. Sameera Hai Baig

Name	Ticker	Share price (last close)	Mkt cap (£mn)	Fwd 12-mth PE	Trailing 12-mth DY	Fwd EPS gwth current FY	Fwd EPS gwth next FY	3-mth share price mom	Net cash (£mn)	Tests passed (out of 9)	Tests failed
Avast	AVST	562.6	5852	18.7	2.7%	7.0%	6.9%	-7%	-147.6	9	na
BHP	BHP	3019	151562	11.7	7.4%	23.1%	-19.0%	37%	-835.4	8	/EPS gwth/
British American Tobacco	BATS	3226	73669	8.9	6.8%	7.5%	9.2%	18%	-11879.0	8	/RoEgrth/
Diageo	DGE	3870	89289	25.3	1.9%	20.1%	11.6%	-4%	-4272.0	8	/EBIT Up/
BAE Systems	BA	713.8	22496	13.9	3.5%	6.4%	6.7%	30%	-5585.0	8	/Margin grth/
Hikma Pharmaceuticals	HIK	2039	4636	12.4	2.0%	10.7%	9.7%	-8%	-417.9	8	/RoE up/
Experian	<b>EXPN</b>	2911	26845	27.2	1.2%	30.7%	13.3%	-20%	-1606.1	8	/EBIT Up/
Sage Group	SGE	717.8	7308	26.2	2.5%	12.7%	12.9%	-16%	-827.0	8	/EBIT Up/
IMI	IMI	1358	3540	13.0	1.7%	11.4%	8.1%	-22%	-630.4	8	/Margin grth/
RioTinto	RIO	6225	77764	7.6	9.3%	-9.6%	-27.8%	27%	1964.6	7	/Genuine value/EPS gwth.
GlaxoSmithKline	GSK	1656.6	84220	13.5	4.8%	6.3%	6.7%	3%	-19335.0	7	/RoE up/EBIT Up/
RELX	REL	2365	45659	23.2	2.1%	13.5%	10.8%	-2%	-3635.0	7	/RoE up/EBIT Up/
Auto Trader	AUTO	638.2	6019	23.6	1.2%	86.7%	9.6%	-14%	20.9	7	/RoEup/EBITUp/
Rightmove	RMV	635	5359	26.5	1.2%	10.6%	6.3%	-20%	20.4	7	/RoEup/EBITUp/
Burberry	BRBY	1673.5	6639	16.4	3.2%	37.3%	10.3%	-8%	558.5	7	/RoEgrth/EBITUp/
Entain	ENT	1652	9718	19.5	0.0%	46.5%	37.8%	-2%	-752.6	7	/Margin grth/RoE grth/
Intertek	ITRK	5214	8415	23.7	2.0%	13.1%	8.0%	-7%	-999.7	7	/RoEup/EBITUp/
Spirax-Sarco Engineering	SPX	12700	9349	35.9	1.1%	3.2%	5.8%	-21%	-107.1	7	/Genuine value/PE/
Berkeley Group	BKG	3728	4178	9.7	0.3%	14.4%	0.9%	-22%	-253.8	7	/RoE up/EBIT Up/
Evraz	EVR	81	1182	0.8	151.4%	15.6%	-51.9%	-87%	-1080.9	7	/EPS gwth/PE/
Future	FUTR	2604	3145	16.0	0.1%	20.0%	6.0%	-32%	134.0	7	/Margin grth/RoE grth/

Name	Ticker	Share price (last close)	Mkt cap (£mn)	Fwd 12-mth PE	Trailing 12-mth DY	Fwd EPS gwth current FY	Fwd EPS gwth next FY	3-mth share price mom	Net cash (£mn)	Tests passed (out of 9)	Tests failed
Centamin	CEY	92	1063	12.4	7.3%	5.1%	15.1%	3%	93.9	8	/RoEgrth/
Spirent Comm.	SPT	236	1446	17.7	2.1%	4.7%	7.7%	-14%	-1.3	8	/RoEup/
Britvic	BVIC	804	2152	14.1	3.0%	22.9%	8.7%	-13%	-493.7	8	/EBIT Up/
Morgan Sindall	MGNS	2390	1108	10.8	3.8%	0.2%	5.1%	-5%	-658.3	8	/Margin grth/
Games Workshop	GAW	7320	2404	18.7	3.6%	3.4%	2.5%	-27%	40.5	8	/Genuine value/
Oxford Instruments	OXIG	2105	1214	24.6	0.8%	8.9%	1.2%	-20%	-46.0	8	/EBIT Up/
Dunelm	DNLM	1077	2179	13.2	12.9%	29.8%	0.2%	-22%	-107.3	8	/RoEup/
Volution	FAN	411	813	17.4	1.6%	9.0%	4.7%	-26%	-52.6	8	/RoEgrth/
888 Holdings	888	194	727	8.8	0.0%	5.4%	11.7%	-35%	-62.4	8	/Margin grth/
Indivior	INDV	285	2012	17.0	0.0%	19.9%	22.1%	11%	220.0	7	/RoE grth/EBIT Up/
Coats	COA	77	1123	12.7	2.1%	15.1%	14.4%	12%	-257.8	7	/RoE up/EBIT Up/
Ultra Electronics	ULE	3324	2375	24.0	0.0%	0.5%	5.5%	5%	-119.9	7	/Genuine value/RoE up
ContourGlobal	GLO	192	1261	25.5	6.8%	14.1%	5.9%	0%	-626.2	7	/RoE grth/Int Cov/
Drax	DRX	776	3105	10.5	2.4%	198.0%	59.7%	28%	-1915.5	7	/Margin grth/RoE grth
Clarkson	CKN	3700	1128	21.1	2.3%	7.9%	-4.4%	-5%	14.6	7	/RoE grth/EPS gwth/
Rotork	ROR	321	2765	24.3	2.0%	15.2%	9.6%	-10%	10.8	7	/RoE up/EBIT Up/
Moneysupermarket.com	MONY	187	1003	13.6	6.3%	9.2%	21.7%	-13%	-95.3	7	/RoE up/EBIT Up/
Cranswick	CWK	3526	1871	16.3	2.0%	6.2%	2.4%	-5%	-192.3	7	/Margin grth/EBIT Up/
Victrex	VCT	1822	1585	18.1	3.3%	15.3%	9.6%	-25%	56.4	7	/RoE up/EBIT Up/
Watches of Switzerland	WOSG	1141	2733	21.9	0.0%	71.1%	30.4%	-20%	-112.7	7	/Margin grth/RoE grth
Spectris	SXS	2531	2806	15.5	2.8%	13.9%	7.6%	-31%	-225.9	7	/RoE grth/EBIT Up/
XP Power	XPP	3465	684	16.5	2.7%	16.3%	10.3%	-32%	-40.0	7	/RoEup/EBITUp/

Continued below





UK small-cap (including Aim-listed) quality selection (passing at least 8 of 9 tests)

		Share price			Trailing 12-	FwdEPS	FwdEPS	3-mth share		Tests passed	Tests
Name	CEY	(last close)	(£mn)	mth PE	mth DY	-	gwth next FY	price mom	(£mn)	(out of 9)	failed
Centamin			1063	12.4	7.3%	5.1%	15.1%	3%	93.9		na
Macfarlane	MACF		205	11.5	2.5%	43.0%	0.0%	0%	-67.4	9	na
SDI	SDI		180	24.5	0.0%	20.6%	0.0%	-7%	-11.9	9	na
Fintel	FNTL		216	17.0	1.4%	17.1%	2.0%	-8%	-10.0	9	na
Alumasc	ALU		71	7.8	4.9%	1.2%	6.8%	-17%	-18.9	9	na
Aferian	AFRN		115	14.2	2.3%	10.0%	15.8%	-14%	-11.6	9	na
Tyman	TYMN		628	9.5	4.0%	3.7%	5.5%	-20%	-68.5	9	na
Keller	KLR		606	8.3	4.3%	11.7%	7.6%	-15%	-524.5	9	na
388 Holdings	888		727	8.8	0.0%	5.4%	11.7%	-35%	-62.4	9	na
Pan African Resources	PAF		517	4.9	3.7%	52.1%	14.2%	39%	-51.3	8	/PE/
Bloomsbury Publishing	BMY	411	335	16.5	4.5%	27.6%	3.8%	14%	-22.7	8	/EBITUp/
Chemring	CHG		916	17.2	1.5%	12.5%	3.2%	9%	-96.7	8	/EBITUp/
Devro	DVO		346	11.2	4.5%	2.4%	5.3%	1%	-18.3	8	/RoEgrth/
MIS	EMIS		857	22.5	2.6%	7.3%	3.6%	0%	2.4	8	/Genuine value
ContourGlobal	GLO		1261	25.5	6.8%	14.1%	5.9%	0%	-626.2	8	/Int Cov/
Clipper Logistics	CLG		908	26.6	1.3%	21.7%	22.9%	21%	-203.4	8	/Int Cov/
ranchise Brands	FRAN	159	201	21.9	0.9%	29.8%	14.6%	4%	-4.4	8	/RoEup/
Central Asia Metals	CAML	240	422	6.3	8.3%	11.1%	-9.8%	-7%	5.3	8	/EPS gwth/
Watkin Jones	WJG	259	663	13.0	3.2%	5.3%	32.0%	-1%	26.8	8	/RoEup/
ZCussons	PZC	201	862	15.4	3.0%	4.5%	6.2%	-2%	-103.3	8	/Genuine value
omero Enterprises	SOM	490	275	10.2	7.8%	3.3%	14	-10%	17.9	8	/EPS gwth/
RBG	RBGP	110	105	10.0	4.5%	24.9%	16.3%	-6%	8.0	8	/EBIT Up/
Fonix Mobile	FNX	152.5	152	17.8	3.6%	12.9%	11.4%	-8%	-20.5	8	/Margin grth/
/itec	VTC	1360	629	15.4	2.6%	21.3%	15.8%	-4%	-105.4	8	/Margin grth/
Cerillion	CER	780	230	23.7	0.9%	11.4%	32.0%	-12%	2.8	8	/Genuine value
Mattioli Woods	MTW	780	398	13.8	2.8%	24.2%	12.9%	-10%	-3.5	8	/RoEup/
Anpario	ANP		132	23.4	1.8%	1.3%	6.4%	-10%	10.3	8	/Genuine value
Animalcare	ANCR		201	26.1	1.3%	4.3%	10.1%	-3%	-8.8	8	/Genuine value
Kape Technologies	KAPE		1384	11.7	0.0%	85.5%	11.3%	-14%	-319.9	8	/Int Cov/
Morgan Sindall	MGNS		1108	10.8	3.8%	0.2%	5.1%	-5%	-658.3	8	/Margin grth/
Gateley	GTLY		240	13.0	5.2%	6.5%	11.4%	-13%	-13.4	8	/RoEup/
Begbies Traynor	BEG		179	12.6	2.6%	26.5%	10.3%	-13%	-31.4	8	/RoEup/
Beximco Pharm. Ltd Sponsored G			695	8.3	2.4%	31.7%	-10.9%	-19%	-73.9	8	/EPSgwth/
Breedon	BREE		1355	12.6	2.0%	28.7%	1.5%	-16%	-195.2	8	/RoEup/
Three	STEM		543	11.7	2.7%	8.4%	10.6%	-13%	-160.9	8	/RoEup/
Bakkavor	BAKK		632	9.6	6.1%	9.5%	6.6%	-14%	-385.0	8	/EBITUp/
Sureserve	SUR		135	9.7	0.1%	14.5%	7.2%	-14%	-36.4	8	/Margin grth/
K3 Capital	K3C		191	11.6	3.9%	7.8%	23.2%	-14%	-30.4	8	/RoEup/
	WATR		150	32.9	0.0%	64.6%	16.9%	-24%	-2.9	8	/EBIT Up/
Water Intelligence NCC											
	NCC		573	14.8	2.5%	212.5%	16.9%	-21%	15.4	8	/RoEup/
Renew	RNWH		550	12.6	2.3%	8.1%	2.5%	-17%	-230.3	8	/RoEup/
olution	FAN		813	17.4	1.6%	9.0%	4.7%	-26%	-52.6	8	/Genuine value
CVS	CVSG		1218	20.1	0.4%	9.7%	5.7%	-23%	-64.8	8	/Genuine value
Craneware	CRW		601	23.6	1.7%	34.9%	8.3%	-30%	134.8	8	/RoEup/
ckoh	ECK		111	18.8	1.6%	41.1%	35.4%	-28%	-7.3	8	/EBITUp/
/ITI Wireless Edge	MWE		51	18.1	3.7%	0.3%	9.7%	-25%	0.0	8	/Genuine value
/esuvius	VSVS		934	8.0	6.2%	18.3%	14.6%	-24%	-353.9	8	/EBITUp/
uceco	LUCE		322	9.8	4.1%	0.7%	8.0%	-43%	-63.3	8	/Genuine value
Jp Global Sourcing	UPGS	130	116	8.9	3.9%	31.6%	6.8%	-36%	-39.3	8	/RoE up/

Continued below





Name	Ticker	Share price (last close)		Fwd 12- mth PE	Trailing 12- mth DY	Fwd EPS gwth cur FY	Fwd EPS gwth next FY	3-mth share price mom	Net cash (\$mn)	Tests passed (out of 9)	Sector
Vertex Pharm. Inc	VRTX	266.15	67756	18.1	0.0%	11.3%	6.2%	21%	5388.0	9	Pharmaceuticals: Major
FLEETCOR Tech, Inc.	FLT	249.6	19440	15.7	0.0%	16.5%	13.8%	12%	-3039.7	9	Miscellaneous Commercial Service
Jack Henry & Associates, Inc.	JKHY	200.42	14596	39.1	0.9%	16.7%	9.0%	20%	-469.9	9	Information Technology Services
FMC Corp	FMC	131.13	16508	16.4	1.5%	11.7%	13.1%	19%	-3003.5	9	Chemicals: Agricultural
Union Pacific Corp	UNP	259.96	163355	21.8	1.7%	16.8%	10.9%	3%	-4719.0	9	Railroads
Johnson & Johnson	JNJ	178.19	468571	16.7	2.4%	7.8%	4.5%	4%	-13618.0	9	Pharmaceuticals: Major
Texas Instruments Inc	TXN	182.08	168038	19.9	2.3%	10.3%	2.3%	-3%	7170.0	9	Semiconductors
Apple Inc.	AAPL	174.31	2844642	27.4	0.5%	9.7%	6.8%	-2%	-62842.0	9	Telecommunications Equipment
CSX Corp	CSX	35.51	77500	19.4	1.1%	6.8%	9.2%	-6%	83.0	9	Railroads
Verisk Analytics Inc	VRSK	214.12	34534	35.6	0.5%	10.2%	10.7%	-6%	-1547.3	9	Data Processing Services
Microsoft Corp	MSFT	309.42	2319681	29.7	0.8%	17.3%	15.0%	-8%	41677.0	9	Packaged Software
Automatic Data Processing, In	c. ADP	233.5	98081	31.6	1.6%	13.3%	11.2%	-5%	-35509.2	9	Data Processing Services
O'Reilly Automotive, Inc.	ORLY	667.43	44451	19.5	0.0%	7.2%	10.9%	-5%	-5512.5	9	Specialty Stores
Cintas Corp	CTAS	423.88	43412	34.8	0.8%	11.2%	8.5%	-4%	-1440.4	9	Other Consumer Services
Nordson Corp	NDSN	227.93	13206	24.4	0.8%	16.9%	7.8%	-11%	-145.4	9	Industrial Machinery
KLA Corp	KLAC	360.27	54298	15.5	1.1%	40.8%	17.6%	-16%	391.3	9	Semiconductors
Skyworks Solutions, Inc.	SWKS	132.03	21345	10.8	1.6%	10.1%	11.0%	-15%	361.6	9	Semiconductors
Fastenal Company	FAST	59.67	34343	32.3	1.9%	13.0%	8.2%	-7%	-446.0	9	Wholesale Distributors
Applied Materials, Inc.	AMAT	127.41	112553	14.7	0.8%	19.0%	15.8%	-19%	-885.0	9	Industrial Machinery
Mettler-Toledo Int'l Inc.	MTD	1371.63	31185	34.9	0.0%	12.3%	11.1%	-19%	-1048.0	9	Medical Specialties
Lam Research Corp	LRCX	525.45	73300	14.1	1.1%	21.1%	17.5%	-27%	2201.3	9	Electronic Production Equipment
Old Dominion Freight Line, Inc	. ODFL	278.5	31990	24.8	0.3%	22.7%	11.1%	-22%	252.8	9	Trucking
Agilent Technologies, Inc.	Α	133.97	40206	26.3	0.6%	12.4%	10.3%	-16%	-133.0	9	Medical Specialties
Generac Holdings Inc.	GNRC	301	19199	24.8	0.0%	20.0%	20.0%	-14%	-1008.6	9	Electrical Products
Keysight Technologies Inc	KEYS	158.4	28825	21.9	0.0%	12.6%	7.9%	-23%	743.0	9	Electronic Equipment/Instruments



Alpha Editor: James Norrington

Alpha Production Editor: Sameera Hai Baig

© The Financial Times Limited 2022. Investors' Chronicle is a trademark of The Finan-cial Times Limited. "Financial Times" and "FT" are registered trademarks and service marks of The Financial Times Limited. All rights reserved. No part of this publication or information contained within it may be commercially exploited in any way without prior permission in writing from the editor.

Permitted Use: By purchasing this magazine, you agree that the intellectual property rights (including copyright and database rights) in its content belong to The Financial Times Limited and/or its licensors. This magazine is for your own personal, non-com-mercial use. You must not use any of the content as part of any commercial product or service, including without limitation any which reduces the need for third parties to use the Investors' Chronicle magazine and/or website, or which creates revenue from the content, or which is to the detriment of our own ability to generate revenues from that content. For example, you must not use any of our content in any syndica-tion, content aggregation, news aggregation, tips aggregation, library, archive or similar service, and you must not capture any such content, whether systematically, regularly or otherwise, in any form of database without our prior written permission. These contractual rights are without prejudice to our rights to protect our intellectual property rights under

Investors' Chronicle adheres to a self-regulation regime under the FT Editorial Code of Practice: A link to the FT Editorial Code of Practice can be found at www.ft.com/editorialcode. Many of the charts in the magazine are based on material supplied by Thomson Datastream and FactSet.

Material (including tips) contained in this magazine is for general information only and is not intended to be relied upon by individual readers in making (or refraining from making) any specific investment decision. Appropriate independent advice should be obtained before making any such decisions. The Financial Times Limited does not accept any liability for any loss suffered by any reader as a result of any such decision.

ISSN 0261-3115.